Journal of affective disorders · 2026
The antidepressant effectiveness of transcranial magnetic stimulation is not impacted by comorbid neurotic, stress-related or somatoform disorders.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kerkel Katharina, Schoisswohl Stefan, Steinecker Lea, Engelke Milena, Abdelnaim Mohamed A, Langguth Berthold, Reissmann Andreas
Аннотация
INTRODUCTION: Depression is frequently accompanied by neurotic, stress-related and somatoform disorders (F4 diagnoses, ICD-10), which are linked to greater severity and poorer treatment outcomes. Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique used for treatment-resistant depression. We investigated whether comorbid F4 diagnoses affect the antidepressant efficacy of different TMS protocols under real-world conditions.
METHODS: We retrospectively analyzed data from 416 in- and outpatients with unipolar or bipolar depression at a German tertiary hospital between 2019 and 2024, of whom 107 had an F4 comorbidity. All patients received left prefrontal TMS: intermittent theta-burst stimulation (iTBS) with 600 (n = 138), 1200 (n = 98), or 1800 pulses per session (n = 104), or tonic repetitive TMS (rTMS) at 20 Hz with 2000 pulses (n = 76). Depressive symptoms were assessed before and after treatment using the HAMD-21 and MDI.
RESULTS: Depression scores improved significantly in both groups, with no significant difference between patients with or without F4-comorbidity. Remission rates were lower in patients with comorbid F4-diagnoses. No significant differences were observed between TMS protocols in patients with F4-comorbidity. Network analyses revealed similar symptom profiles in both groups.
CONCLUSION: Comorbid F4-diagnoses do not affect the antidepressant efficacy of TMS. iTBS is as effective as other protocols, but shorter and more cost-efficient, making it preferable for patients and providers.
METHODS: We retrospectively analyzed data from 416 in- and outpatients with unipolar or bipolar depression at a German tertiary hospital between 2019 and 2024, of whom 107 had an F4 comorbidity. All patients received left prefrontal TMS: intermittent theta-burst stimulation (iTBS) with 600 (n = 138), 1200 (n = 98), or 1800 pulses per session (n = 104), or tonic repetitive TMS (rTMS) at 20 Hz with 2000 pulses (n = 76). Depressive symptoms were assessed before and after treatment using the HAMD-21 and MDI.
RESULTS: Depression scores improved significantly in both groups, with no significant difference between patients with or without F4-comorbidity. Remission rates were lower in patients with comorbid F4-diagnoses. No significant differences were observed between TMS protocols in patients with F4-comorbidity. Network analyses revealed similar symptom profiles in both groups.
CONCLUSION: Comorbid F4-diagnoses do not affect the antidepressant efficacy of TMS. iTBS is as effective as other protocols, but shorter and more cost-efficient, making it preferable for patients and providers.